000			03508nam a22003855i 4500
001			287161
003			MX-SnUAN
005			20160429154535.0
007			cr nn 008mamaa
008			150903s2013 xxk| o |||| 0|eng d
020			_a9781447142973 _99781447142973
024	7		_a10.1007/9781447142973 _2doi
035			_avtls000339777
039		9	_a201509030319 _bVLOAD _c201404300405 _dVLOAD _y201402060943 _zstaff
040			_aMX-SnUAN _bspa _cMX-SnUAN _erda
050		4	_aRC681-688.2
100	1		_aFerro, Albert. _eeditor. _9316212
245	1	0	_aAntiplatelet and Anticoagulation Therapy / _cedited by Albert Ferro, David A. Garcia.
264		1	_aLondon : _bSpringer London : _bImprint: Springer, _c2013.
300			_ax, 247 páginas 37 ilustraciones, 26 ilustraciones en color. _brecurso en línea.
336			_atexto _btxt _2rdacontent
337			_acomputadora _bc _2rdamedia
338			_arecurso en línea _bcr _2rdacarrier
347			_aarchivo de texto _bPDF _2rda
490	0		_aCurrent Cardiovascular Therapy
500			_aSpringer eBooks
505	0		_aAntiplatelet agents: current and novel -- Antiplatelet Drug Resistance and Variability in Response: The Role of Antiplatelet Therapy Monitoring -- Anticoagulant Drugs: Current and Novel -- Primary prevention of cardiovascular disease -- Approaches to the Prophylaxis and Treatment of Venous and Cardiac Thromboembolic Disease.
520			_aAspirin has been in clinical use for over 100 years, making it one of the oldest commonly used drugs in medicine, and is now predominantly used as an antiplatelet agent. Major new antiplatelet drug classes have recently become available for the clinician that offer the promise of major improvements in the treatment and prevention of arterial thrombotic disease. In the field of anticoagulation, the vitamin K antagonists such as warfarin have not been available for as long as aspirin in the antiplatelet field, and have also had very little in the way of competition until recently; although a number of parenteral anticoagulants have been available, the vitamin K antagonists have been the only orally active anticoagulant drugs. The last few years have seen the arrival of new drug classes, the orally active direct thrombin inhibitors and factor Xa antagonists, which offer a number of advantages, but not without important drawbacks. In the face of these important advances in both antiplatelet and anticoagulant therapy, clinicians often feel confused, even overwhelmed, as to what is now available and which drugs are useful (and indicated) in which circumstances. Antiplatelet and Anticoagulant Therapy is designed with such people in mind. It is written in an easy-to-follow format and with many illustrations to aid clarity and the assimilation of information. Each chapter is written by established authorities in their fields who are also experienced in explaining often complex concepts. The result is a unique book which is not only comprehensive but also clear and useful for the busy medical practitioner.
590			_aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700	1		_aGarcia, David A. _eeditor. _9316213
710	2		_aSpringerLink (Servicio en línea) _9299170
776	0	8	_iEdición impresa: _z9781447142966
856	4	0	_uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-1-4471-4297-3 _zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942			_c14
999			_c287161 _d287161